Pulmonary fibrosis secondary to COVID-19: a call to arms?Paolo Spagnolo, Toby M. Maher|The Lancet Respiratory Medicine|2020Cited by 498
PD-1 up-regulation on CD4 <sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 productionLindsay J. Celada, Wonder P. Drake, Jonathan A. Kropski et al.|Science Translational Medicine|2018Cited by 364
Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association studyRichard J. Allen, Gísli Jenkins, William A. Fahy et al.|The Lancet Respiratory Medicine|2017Cited by 299
Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary FibrosisMichael Kreuter, Toby M. Maher, Joyce Lee et al.|American Journal of Respiratory and Critical Care Medicine|2021Cited by 198
Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort studyJose D. Herazo‐Maya, Naftali Kaminski, Jiehuan Sun et al.|The Lancet Respiratory Medicine|2017Cited by 191